Chiltern Finalizes Acquisition of Theorem Clinical Research
(London, U.K., and Wilmington, N.C.; Sept. 14, 2015) -
Chiltern now comprises 3,700 people across 47 countries, expanding Chiltern’s footprint in Europe, North America and Asia-Pacific. The acquisition enhances Chiltern’s
“By bringing Chiltern and Theorem together, we have created a unique, mid-sized research partner focused on providing exceptional scientific expertise and personal service,” said
“The acquisition of Theorem marks an important milestone for Chiltern,” said
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Related Articles
- Everything to Know About FDA’s Push Towards Radical Transparency in 2025
September 17th 2025
- IQVIA and Veeva Join Forces to Improve Efficiency and Patient Outcomes
September 17th 2025
- Managing Background Therapies in the NIMBLE Phase III Trial
September 17th 2025
- Generative AI Transforms Clinical Study Report Development
September 16th 2025